Bethanechol Chloride for prevention of bladder dysfunction after radical hysterectomy in gynecologic cancer patients: A Randomised controlled trial study

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN92687416

Enrollment

Registered

2010-07-29

Start date

2007-08-01

Completion date

Unknown

Last updated

2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bladder dysfunction after radical hysterectomy Urological and Genital Diseases Other disorders of bladder

Interventions

Treatment group received bethanechol chloride (Ucholine®) 20 mg three times a day, 1 hour before meal on 3rd -7th postoperative day (POD). The control group received a placebo which had a similar app

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Early stage cervical cancer or endometrial cancer patients who have undergone type III radical hysterectomy 2. Age 20-75 years

Exclusion criteria

Exclusion criteria: 1. Hypersensitivity to bethanechol chloride 2. Active bronchial asthma 3. Hyperthyroidism 4. Hypotension 5. Tachycardia 6. Vasomotor instability 7. Coronary artery disease 8. Epilepsy 9. Parkinsonism 10. Gastrointestinal obstruction 11. Bladder neck obstruction 12. Recent urinary bladder surgery 13. Gastrointestinal resection with anastomosis

Design outcomes

Primary

Measure	Time frame
The incidence of urethral catheter removal at 1 week postoperatively	—

Secondary

Measure	Time frame
1. Median duration of urethral catheterization 2. Adverse events 3. Incidence of urinary tract infection at 1 month postoperatively	—

Countries

Thailand

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Mar 29, 2026